Biodexa's Phase 3 eRapa trial for FAP reaches two-thirds enrollment
BDRX•Biodexa Pharmaceuticals enrolled 112 of 168 planned participants in its Phase 3 Serenta trial of eRapa for familial adenomatous polyposis; a futility analysis could occur in early 2027, with topline results potentially due around year-end.
1. Trial enrollment update
Biodexa Pharmaceuticals enrolled 112 of 168 planned participants in its Phase 3 Serenta trial of eRapa for familial adenomatous polyposis. A futility analysis could occur in early 2027, with database lock and topline results potentially due around year-end, sooner than originally expected.
2. Other development plans
The company expects its planned Phase 1a trial of MTX240 for treatment-resistant gastrointestinal stromal tumors to begin recruiting in South Korea in mid-2027. A Phase 1b dose-optimization study will follow immediately, and a pre-IND meeting with the FDA is scheduled for December 10, 2026.
